Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on Long-term Benefits and Safety of DBV712 for Children with Peanut Allergy

Fast replyInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying peanut allergy in children. The trial will use a treatment called Viaskin Peanut, which is a patch applied to the skin. The patch contains a small amount of peanut extract and is designed to help children with peanut allergies become less sensitive to peanuts over time. The study will also involve an oral paste made from peanut flour in different doses, including a low dose, a high dose, and a placebo, which is a substance with no active ingredient.

The purpose of the study is to evaluate the long-term benefits and safety of using Viaskin Peanut for up to three years. Children participating in the study will receive the treatment and be monitored to see if they become less sensitive to peanuts. The study will also check for any side effects or reactions to the treatment. The children will be given the treatment over a period of time, and their response to peanuts will be tested at different stages to see if the treatment is effective.

Throughout the study, researchers will collect information on how well the children tolerate peanuts and any changes in their allergy symptoms. The study aims to help understand if this treatment can provide a long-term solution for children with peanut allergies, making it safer for them to be around peanuts without having severe allergic reactions. The study will also look at the overall health and quality of life of the children during the treatment period.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after completing the previous EPITOPE study and signing the informed consent form by the parent or guardian.

    The consent must be signed after completing the Month 12 procedures in the EPITOPE study.

  2. Step 2

    Initial assessment

    An initial assessment is conducted to confirm eligibility and establish baseline measurements.

    This includes a double-blind, placebo-controlled food challenge (DBPCFC) to determine the initial dose of peanut protein that can be tolerated.

  3. Step 3

    Treatment phase

    The treatment involves the use of Viaskin Peanut, a cutaneous patch applied to the skin.

    The patch contains 250 micrograms of peanut protein and is used for up to 3 years.

    The goal is to induce or maintain desensitization to peanuts.

  4. Step 4

    Regular monitoring

    Regular monitoring is conducted to assess the clinical benefit and safety of the treatment.

    This includes evaluating the proportion of subjects reaching specific doses of peanut protein without symptoms.

    Safety assessments include monitoring for adverse events and reactions at the patch site.

  5. Step 5

    Follow-up assessments

    Follow-up assessments are conducted at intervals to measure the sustained clinical benefit.

    These assessments include additional DBPCFCs to evaluate changes in peanut protein tolerance.

  6. Step 6

    Completion of study

    The study is estimated to conclude by May 29, 2025.

    Final assessments will be conducted to evaluate the long-term effects of the treatment.

Who can join the trial?

6 criteria

  • The child must have a **peanut allergy**.
  • The child's parent(s) or guardian(s) must sign a form called an **informed consent form**. This form shows they understand the study and agree to let their child participate.
  • The child must have completed a previous study called the **EPITOPE study**. This includes finishing a specific test called **DBPCFC** (Double-Blind Placebo-Controlled Food Challenge) at the 12-month mark of that study.
  • The child's parent(s) or guardian(s) and the child must be willing to follow all the rules and requirements of the study while participating.
  • The study is open to both boys and girls.
  • The study is for children aged 2 years and older.

Who cannot join the trial?

8 criteria

  • Children who do not have a peanut allergy cannot participate. A peanut allergy is when the body reacts badly to peanuts, causing symptoms like itching or swelling.
  • Children who are not between the ages of 2 and 17 cannot participate.
  • Children who have other serious health conditions that might interfere with the study cannot participate.
  • Children who are taking medications that might affect the study results cannot participate.
  • Children who have participated in other similar studies recently cannot participate.
  • Children who have a history of severe allergic reactions that are not related to peanuts cannot participate.
  • Children who have skin conditions that might affect the treatment cannot participate.
  • Children who are unable to follow the study instructions cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Viaskin Peanut is a treatment designed for children with peanut allergies. It is used in a method called epicutaneous immunotherapy, where the medication is applied to the skin. The goal of this treatment is to help children become less sensitive to peanuts over time, potentially allowing them to tolerate small amounts of peanuts without having an allergic reaction. This study aims to evaluate the long-term benefits and safety of using Viaskin Peanut for up to three years.

What is already known about the treatment

Viaskin Peanut – This medication is administered through a patch applied to the skin, known as epicutaneous immunotherapy. It is currently being studied in clinical trials for its long-term benefits and safety in treating peanut allergies in children. The main therapeutic indication is to help desensitize children to peanuts, reducing allergic reactions. At the molecular level, it works by gradually exposing the immune system to small amounts of peanut protein, aiming to build tolerance. It is classified as an immunotherapy treatment.

Investigated diseases

Peanut Allergy – Peanut allergy is a common food allergy that occurs when the immune system mistakenly identifies proteins in peanuts as harmful. This triggers an allergic reaction, which can range from mild symptoms like hives or itching to more severe reactions such as difficulty breathing or anaphylaxis. The progression of peanut allergy can vary; some individuals may experience more severe reactions over time, while others may have consistent symptoms. It is often diagnosed in childhood, and while some children may outgrow it, many continue to have the allergy into adulthood. The condition requires strict avoidance of peanuts and peanut-containing products to prevent allergic reactions.
Trial detailsLast updated 2 Oct 2026
Age0-17PhasePhase IIITrial ID2024-515703-19-00Protocol codeV712-305/EPOPEXEstimated enrolment288 patientsSponsorDbv Technologies

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).